Seroprevalence of Hepatitis E IgG Antibodies Among Voluntary Blood Donors in a Tertiary Hospital

C P Luck1, Jamunarani Srirangaramasamy1*, Duraipandian Jeyakumari2, Madasamy Balamurugan1
Aruna Padmavathi V1 and Kolsamma Nasrin1

Department of Pathology, Tagore Medical college and Hospital, Rathinamangalam, Chennai, Tamilnadu, India
Department of Microbiology, Tagore Medical college and Hospital, Rathinamangalam, Chennai, Tamilnadu, India

ABSTRACT

Background: Transfusion safety is a major concern in medical practice. Hepatitis E is a potential threat among transfusion-transmitted infections. In resource poor settings and in endemic countries, parenteral transmission can occur at an increased rate and leads to subclinical infection. Currently Hepatitis E virus screening is not mandatory in many countries. This can possibly endanger the population.

Materials and Methods: We aimed at estimating the seroprevalence of HEV antibodies (IgG) among healthy blood donors in Chennai, South India. A prospective study was conducted among 142 blood donors from January 2016 to November 2016 in a tertiary care teaching hospital. Serum anti HEV IgG antibody was detected by Enzyme Linked Immuno Sorbent Assay (ELISA).

Results: Out of 142 samples, 19/142 (13.38%) showed positivity for IgG antibodies for HEV.

Conclusion: This study showed the importance of screening for HEV, as there is increased rate of positivity among the blood donors in our study population.

Keywords: Hepatitis E, Parenteral Transmission, Blood Transfusion, Maternal Mortality, HEV IgG

Introduction

Hepatitis E is an enterically transmitted infectious virus, which causes acute self-limiting hepatitis. Initially it was considered as only water borne outbreak infection, now it has been proven that there are other modes of transmissions like zoonotic transmission, person-to-person transmission and through blood transfusion. Transfusion transmitted infections (TTI) are one among the major risks during blood transfusion. Among them, most commonly screened infections during blood and blood products transfusion in health care centers are as follows: Human immuno deficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), syphilis and malaria. Other least common infections screened are Toxoplasmosis, Leishmaniasis and Hepatitis E virus (HEV). Developed countries have a constant vigilance in the estimation of prevalence of transfusion related HEV infections. It was estimated that 80,000 to 1,00,000 HEV infections had occurred due to transfusion in England in 2013, with seroprevalence rate of 6.8% and annual incidence rate of 0.35%. Studies in developing countries like India are very limited and only little evidence is available till now. In a study conducted among blood donors in Pune, 1.5% of HEV RNA was estimated during the year 2000 and 3.7% during the year 2004. Blood transfusions are carried out in critically ill cases that include solid organ transplantation, pregnancy, hematological disorders and neoplasm. Hepatitis E, even though most commonly causes self limiting diseases, in the above said critically ill and immunocompromised cases, it leads to more severe presentations that may end up in chronic hepatitis and cirrhosis. Though acute morbidity due to transmission of HEV infection through blood transfusion is rare and supporting evidences are still lacking, studies need to be explored in all developing countries to know the real burden of transfusion transmitted HEV infections. Hence we aimed at estimating the seroprevalence of HEV IgG antibodies among healthy blood donors in our tertiary hospital, Chennai, South India.

Materials and Methods

A prospective study was conducted in the Department of transfusion medicine in a tertiary care teaching hospital in Chennai, South India. Institutional ethical committee approval was obtained and the serum samples were anonymized. By simple random sampling, 142 samples of the healthy donors were chosen as study population during the study period of January to November 2016. Serum anti HEV IgG antibody was detected by Enzyme Linked ImmunoSorbent Assay (ELISA). Third generation enzyme immune assay for the detection of IgG antibodies to Hepatitis E virus kit (Diagnostic Bioprobes Srl Via G. Carducci n° 27 20099 Sesto San Giovanni - Italy) was used and procedure was done as per manufacturer instructions.
The sensitivity and specificity of the kit is 100%. The positive cases were retested in duplicate. The results were tabulated in MS office Excel 2016 and analyzed using SPSS software.

**Results**

The study population that included 142 samples showed predominant gender distribution of 141 males and 1 female donor. The range of age is from 18 years to 51 years with a mean age of 25 years. Age distribution was analyzed by stratification of age group into 18-20 years (33.09%), 21-30 years (49.29%), 31-40 years (13.38%), 41-50 years (3.52%) and 51-60 years (0.7%).

Out of 142 samples, 19/142 (13.38%) showed positivity for anti-IgG antibodies for HEV. The distribution of HEV positive cases based on age stratification is depicted in Figure 1.

Table 1: Comparative evidence of seroprevalence of Hepatitis E among blood donors in different countries.

<table>
<thead>
<tr>
<th>Study Place</th>
<th>Study Year</th>
<th>Methodology</th>
<th>Detection</th>
<th>Sero-prevalence</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
<td>1998</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>2.8</td>
<td>(13)</td>
</tr>
<tr>
<td>Pune, India</td>
<td>2000</td>
<td>PCR</td>
<td>HEV RNA</td>
<td>1.5</td>
<td>(5)</td>
</tr>
<tr>
<td>United States</td>
<td>2002</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>18.3</td>
<td>(14)</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>2004</td>
<td>ELISA</td>
<td>HEV IgM</td>
<td>8.96</td>
<td>(6)</td>
</tr>
<tr>
<td>Pune, India</td>
<td>2007</td>
<td>PCR</td>
<td>HEV RNA</td>
<td>0</td>
<td>(18)</td>
</tr>
<tr>
<td>South west France</td>
<td>2007</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>16.6</td>
<td>(17)</td>
</tr>
<tr>
<td>Japan</td>
<td>2007</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>7.1</td>
<td>(19)</td>
</tr>
<tr>
<td>Gujarat, India</td>
<td>2012</td>
<td>ELISA</td>
<td>HEV IgM</td>
<td>4.78</td>
<td>(12)</td>
</tr>
<tr>
<td>Southeast England</td>
<td>2012</td>
<td>PCR</td>
<td>HEV RNA</td>
<td>0.04</td>
<td>(7)</td>
</tr>
</tbody>
</table>
### Discussion

In our study, among a total of 142 voluntary blood donors screened for HEV antibodies, 13.38% showed seropositivity. Gender preponderance for HEV infection cannot be concluded from our study, as there is male dominance in study population. However certain studies conducted at Japan and Iran have shown a male preponderance. In contrary, studies from France and Brazil have shown no difference among gender distribution in HEV seroprevalence.\(^{8,9,10}\) Age stratification has shown that majority of the positives are amongst younger age group 8/47 (17.02%) among 18-20 years followed by 11/70 (15.71%) among 21-30 years. None of the population above the age group of 31 years showed positivity. This may be contrary to the study conducted in western India, which showed increased positivity among older age groups supported by studies in USA and Denmark.\(^{11,12,13,14}\) This may be due to decreased number of study population in age group more than 31 years.

Seroprevalence rate in our study is comparable with the higher prevalence as seen in southwest France and England.\(^{15,16,17}\) Few Indian studies have shown lesser seroprevalence rates of 1.5% and 3.7%, but the methodology used was polymerase chain reaction, which detected HEV RNA.\(^{5,6}\) Comparison of prevalence rates among different studies are represented in Table 1.

The reasons behind these variations may be due to different sample size, different age groups and due to different methodology used that included serological methods and molecular methods.

---

**Table 1: Study Place, Year, Methodology, Detection and Sero-prevalence**

<table>
<thead>
<tr>
<th>Study Place</th>
<th>Study Year</th>
<th>Methodology</th>
<th>Detection</th>
<th>Sero-prevalence</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>2013</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>6.8</td>
<td>(4)</td>
</tr>
<tr>
<td>Central Italy</td>
<td>2014</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>49</td>
<td>(20)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HEV IgM</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HEV RNA</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>Punjab, India</td>
<td>Not given</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>10.7</td>
<td>(21)</td>
</tr>
<tr>
<td>Chennai, India</td>
<td>2016</td>
<td>ELISA</td>
<td>HEV IgG</td>
<td>13.38</td>
<td>Current study</td>
</tr>
</tbody>
</table>

---

**Fig. 1: Age wise distribution of study population and HEV seropositivity.**
Seroprevalence rates are detected based on the presence of anti-HEV IgG in blood. Though the duration of persistence of anti-HEV IgG in blood after exposure is not certain, it mainly depend upon immune status of individual and other factors. Antibody levels are in peak during acute phase of illness and it may persist up to a maximum of 12 years or even more. Clinical risk of transmission of infection can be evidenced only by detection of viremia either in asymptomatic form or in subclinical presentation. Studies estimating seroprevalence helps in estimating the burden of HEV. However only HEV RNA detection aids in identifying viremic cases and transmission related risk could be estimated with increased specificity. Since molecular methods are limitedly used only for epidemiological studies due to cost factor; serological methods using more sensitive and specific kits (anti HEV IgM and anti HEV IgG) is mandatory in all health care centers.

Limitations of our study are small sample size, increased distribution of younger age groups in study population and molecular method couldn’t be used due to increased cost. Future plan has been proposed to conduct studies overcoming the above limitations.

**Conclusion**
The above study throws light about screening for HEV in blood donors in general. Though little knowledge is available about HEV transmission risk during blood transfusion, in endemic countries it is Advisory to screen the blood and blood products for HEV for effective prevention. More longitudinal studies need to be conducted in all health care centers to estimate the burden of HEV among Indian population, so that a national policy can be implemented to screen and prevent transmission of HEV during blood transfusion.

**References**


